FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
... 1%), and fatigue (6% vs. 2%).(5)
The bipolar mania
submission was based on a clinical study of ... was change from baseline in YMRS(**) (Young mania
total score compared to placebo at ... disorder consists of recurring episodes of mania
depression.(2) Bipolar I disorder is ...
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
... (mania) to extreme lows
(depression). Signs of mania
include euphoria, extreme irritability or
rage, ... the treatment of schizophrenia, bipolar mania
and the treatment of
symptoms associated with ... had no crisis interventions; the
subject's Young mania
Rating Scale (YMRS) and Montgomery-Asberg ...
Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
... 960 adult patients with moderate-to-severe mania
with bipolar I disorder received ... produced
significant mean improvements in mania
symptoms versus placebo as measured
by changes in YMRS (Young mania
Rating Scale) score. The YMRS is an 11-item
FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
... 13-17 and for the short-term
treatment of bipolar mania
associated with manic or mixed episodes ... years and for the
short-term treatment of bipolar mania
associated with bipolar I disorder in
children ... for the treatment of
schizophrenia, bipolar mania
and irritability associated with ...
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
... be used cautiously in patients with a history or family history of mania
or hypomania. -- Caution is advised in administering PRISTIQ to patients ... hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania
have been reported and may represent precursors to emerging ...
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
... review by the U.S. Food and Drug Administration (FDA) and includes data from a clinical trial program involving more than 3,000 patients in bipolar mania
and schizophrenia trials. In Europe, a Marketing Authorization Application (MAA) for asenapine, under the brand name SYCREST(R), is currently under ...
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
... New Drug Application (NDA) for asenapine includes data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and ...
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
... As the company celebrates its 50th year in mental health, it currently markets prescription medications for the treatment of schizophrenia, bipolar mania
and the treatment of symptoms associated with autistic disorder. For more information about Janssen, visit www.janssen.com .
J&JPRD and ...
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
... adverse events associated with the use of SEROQUEL versus
placebo in clinical trials as adjunct therapy with lithium or divalproex in
were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia
(10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural
Schering-Plough Completes Acquisition of Organon BioSciences
... Asenapine (from Organon), a fast-dissolving, sublingual psychopharmacologic agent for the treatment of patients with schizophrenia and acute mania
bipolar disorder; * Corifollitropin alfa (from Organon), a new fertility hormone; * Golimumab, an anti-inflammatory for the treatment of ...
Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
... will continue to acquire patient share in all
lines of therapy, largely owing to its first-in-class status among the
antipsychotics to treat both mania
and depression. Janssen's Risperdal and
Eli Lilly's Zyprexa suffered the greatest losses, losing a combined 11.9%
patient share first line over the ...
Psychologist - technology entrepreneurs frequently experience hypomania
... Hypomania occurs in about 5 to 10 percent.
He further explains that mania
and hypomania are biologically related as well. Both conditions run ... that a certain combination of genes produces the undesirable disease of mania
while a more frequent combination produces the advantageous outcome of ...
Hey Willie, Wisconsin Manufacturing Doesnt Need an Aid Concert!
... capital. Both the jobs and the money were destined to evaporate along with the Internet promise of a New Economy.
In the end, the Internet mania
joins tulips, railroads and radio in the graveyard of hyperbole. And I say, Good riddance!
Let no one misunderstand me! The gut-wrenching process ...
Japan's pharma mergers will trickle to the Midwest
... acquisitions by foreign companies of Japanese foreign companies as well as mergers within Japan:
So why is all this Japanese merger mania
happening now ? Well, lets start with the Japanese pharma market itself in relationship with the rest of the world.
The Japanese pharma market ...
Japanese biotech is booming and linked with Midwest
... Earlier this year, I talked about merger mania
in the Japanese pharmaceutical market. Another interesting trend is the growth of Japanese biotechnology. Though the Japanese were slow to ...
Centralization mania takes over
... I don't know if you've noticed but the IT industry is gripped in a mania
for centralization right now. If this were fashion, we'd be talking about the new black, but since it's technology, I'll have to settle for saying ...
How to relate to likes of Ballmer, Jobs, and Ellison
... So since they need you as much as you need gainful employment, Gartner's advice is to use this knowledge as a shied whenever their arrogant and edgy mania
reaches a fever pitch.
"Don't take it personally," Gartner said. "Take a deep breath. Understand it's just him."
Wisconsin firms won't rush to adopt Microsoft Vista
... with the improved search functions. "It allows for a much deeper search, which is also easier to manage," he said.
hasn't spread far, and Jaeck and Luter recommend a measured approach to adoption. Outside of Sonic Foundry's engineers and software developers, Jaeck ...